ЕКЗОСОМОМІМЕТИКИ З КЛІТИН — ПРИРОДНИХ КІЛЕРІВ ЯК ПРИРОДНІ НАНОНОСІЇ ДЛЯ ДОСТАВКИ IN VITRO ХІМІОТЕРАПЕВТИЧНИХ ЗАСОБІВ ДО КЛІТИН РАКУ ЩИТОПОДІБНОЇ ЗАЛОЗИ
Background. Exosomes have become a potential field of nanotechnology for the treatment and identification of many disorders. However, the generation of exosomes is a difficult, time-consuming, and low-yielding procedure. At the same time, exosome mimetics (EM) resemble exosomes in their characterist...
Saved in:
| Date: | 2024 |
|---|---|
| Main Authors: | , |
| Format: | Article |
| Language: | English |
| Published: |
PH Akademperiodyka
2024
|
| Subjects: | |
| Online Access: | https://exp-oncology.com.ua/index.php/Exp/article/view/434 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Journal Title: | Experimental Oncology |
Institution
Experimental Oncology| Summary: | Background. Exosomes have become a potential field of nanotechnology for the treatment and identification of many disorders. However, the generation of exosomes is a difficult, time-consuming, and low-yielding procedure. At the same time, exosome mimetics (EM) resemble exosomes in their characteristics but have higher production yields. The aim of this study was to produce natural killer (NK) cell-derived EM (NKEM) loaded with sorafenib and test their killing ability against thyroid cancer cell lines. Materials and Methods. Sorafenib was loaded into NKEM by mixing sorafenib with NK cells during NKEM production (NKEM-S). Then, these two types of nanoparticles were characterized with nanoparticle tracking analysis (NTA) to measure their sizes. In addition, the cellular uptake and in vitro killing effect of NKEM-S on thyroid cancer cell lines were investigated using confocal laser microscopy and bioluminescence imaging (BLI) techniques. Results. The uptake of NKEM and NKEM-S by the thyroid cancer cells was observed. Moreover, BLI confirmed the killing and anti-proliferation effect of NKEM-S on two thyroid cancer cell lines. Especially important, the NKEM-S demonstrated a desirable killing effect even for anaplastic thyroid cancer (ATC) cells. Conclusion. Sorafenib-loaded NKEM showed the ability to kill thyroid cancer cells in vitro, even against ATC. This provides a new opportunity for drug delivery systems and thyroid cancer treatment. |
|---|